



an Open Access Journal by MDPI

## Immunosuppressive Signaling Regulation in Cancer Development 2.0

Guest Editors:

**Dr. Demin Cai**

College of Animal Science and  
Technology, Yangzhou University,  
Yangzhou, China

**Dr. Chengfei Liu**

Department of Urologic Surgery,  
UC Davis Comprehensive Cancer  
Center, Sacramento, CA, USA

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editors

Dear Colleagues,

Over the past few decades, new conceptual and technical advances in immunology have led to novel discoveries between the immune system and tumors. In 2017, the immune checkpoint inhibitor pembrolizumab was approved to treat solid tumors with mismatch repair genes (MMR) and/or exhibit microsatellite instability (MSI). However, only a small number of cancer patients have the MMR mutations, and the benefits are yet to fully materialize in the context of solid tumor patients. Therefore, there is a significant unmet clinical need to unravel and target pathways that facilitate the emergence of resistant disease to immune surveillance breakthrough.

The aim of this Special Issue is to gather emerging research in cancer immunology and immunometabolism and discover the underlying mechanisms of immune evasion in cancer immunotherapy.

Dr. Demin Cai  
Dr. Chengfei Liu  
*Guest Editors*



[mdpi.com/si/160301](https://mdpi.com/si/160301)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI